Helen Yang, Oricell CEO

In push to ex­pand its CAR-T ther­a­pies to US, Chi­na biotech Ori­cell rais­es ad­di­tion­al $45M

Shang­hai biotech Ori­cell has raised an ad­di­tion­al $45 mil­lion to bankroll its pre­clin­i­cal and ear­ly-stage can­cer cell ther­a­pies, it an­nounced Tues­day morn­ing.

Fol­low­ing a show­ing at AS­CO last year with a GPRC5D-di­rect­ed CAR-T ther­a­py for mul­ti­ple myelo­ma, Ori­cell raised a $120 mil­lion Se­ries B in Ju­ly. The lat­est raise is an ex­ten­sion of that round, and was led by RTW In­vest­ments and Qatar In­vest­ment Au­thor­i­ty, fol­lowed by ex­ist­ing in­vestors Qim­ing Ven­ture Part­ners and C&D Emerg­ing In­dus­try Eq­ui­ty In­vest­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.